Pfizer manufactures Celebrex and in 2004 the sales of Celebrex was $3.3 billion worldwide. But after widespread concerns about the drug causing heart attacks the company stopped advertising. But 16 months later the has returned to the consumer ad market in hopes of reviving sales of the drug, which plunged last year during the ad moratorium. Now the new ads feature mixed reactions of warning and also had ingredients that could boost it sales. Each ad includes a boldface warning about the drugs increased chance of inducing a heart attack or stroke that can lead to death.
Dr. Sidney Wolfe, a frequent critic of drug makers said that there is no evidence of any unique benefit with this drug but has a unique risk factor associated with it. Pfizer stopped advertising Celebrex after Merck stopped selling Vioxx, because of its heart dangers. But federal regulators ordered Pfizer to put a so-called black-box warning on Celebrex, detailing its risks and continue selling the drug. Andrew McCormick, a Pfizer spokesman said that all painkillers carry some risk and that the ads disclose Celebrex's potential dangers. Celebrex is far more expensive than the older painkillers, costing about $3 a pill.